Overview

Hestia Therapeutics, lending its name from the Greek goddess of the hearth, aims to bring inflammatory cells into the tumor microenvironment to unleash anti-tumor effects from within. Currently, more than 70% of cancer patients have tumors that are shielded from the immune cells directed by checkpoint inhibitors to kill cancer cells, leading to disease progression. Hestia is looking to provide a novel approach that will profoundly impact the lives of this segment of cancer patients.